Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

190 ARTÍCULOS , VIENDO DEL 166 AL 180

The relationship between unimanual capacity and bimanual performance in children with congenital hemiplegia

Sakzewski L, Ziviani J, Boyd R.

Dev Med Child Neurol. 2010 Sep;52(9):811-6. doi: 10.1111/j.1469-8749.2009.03588.x. Epub 2010 Jan 28.

Marked improvement in Segawa syndrome after L-dopa and selegiline treatment

Yosunkaya E, Karaca E, Basaran S, Seven M, Yüksel A.

Pediatr Neurol. 2010 May;42(5):348-50. doi: 10.1016/j.pediatrneurol.2010.01.008.

A child with progressive dystonia, dysarthria, and spasticity

Schrock LE, Ostrem JL.

Rev Neurol Dis. 2010;7(1):32-3; discussion 39-42.

Combined ablative neurosurgical procedures in a patient with mixed spastic and dystonic cerebral palsy

Sitthinamsuwan B, Chanvanitkulchai K, Nunta-Aree S, Kumthornthip W, Pisarnpong A, Ploypetch T.

Stereotact Funct Neurosurg. 2010;88(3):187-92. doi: 10.1159/000313872. Epub 2010 May 1.

Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children

Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D.

Dev Med Child Neurol. 2010 May;52(5):e83-7. doi: 10.1111/j.1469-8749.2009.03483.x.

An update on the neurologic applications of botulinum toxins

Evidente VG, Adler CH.

Curr Neurol Neurosci Rep. 2010 Sep;10(5):338-44. doi: 10.1007/s11910-010-0129-z.

International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction

Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB.

Eur J Neurol. 2010 Aug;17 Suppl 2:1-8. doi: 10.1111/j.1468-1331.2010.03125.x.

Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement

Rawicki B, Sheean G, Fung VS, Goldsmith S, Morgan C, Novak I; Cerebral Palsy Institute.

Eur J Neurol. 2010 Aug;17 Suppl 2:122-34. doi: 10.1111/j.1468-1331.2010.03132.x.

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®

Frevert J.

Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000.

Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF.

Mov Disord. 2010 Oct 15;25(13):2211-8. doi: 10.1002/mds.23254.

Assessment and treatment of movement disorders in children with cerebral palsy

Deon LL, Gaebler-Spira D.

Orthop Clin North Am. 2010 Oct;41(4):507-17. doi: 10.1016/j.ocl.2010.06.001.

How to clinically assess and treat muscle overactivity in spastic paresis

Yelnik AP, Simon O, Parratte B, Gracies JM.

J Rehabil Med. 2010 Oct;42(9):801-7. doi: 10.2340/16501977-0613.

Botulinum toxin type A: Exploring new indications

Brashear A.

Drugs Today (Barc). 2010 Sep;46(9):671-82. doi: 10.1358/dot.2010.46.9.1524356.

Use of botulinum toxin in the neurology clinic

Lim EC, Seet RC.

Nat Rev Neurol. 2010 Nov;6(11):624-36. doi: 10.1038/nrneurol.2010.149. Epub 2010 Oct 12.

Semi-dominant X-chromosome linked learning disability with progressive ataxia, spasticity and dystonia associated with the novel MECP2 variant p.V122A: akin to the new MECP2 duplication syndrome?

McWilliam C, Cooke A, Lobo D, Warner J, Taylor M, Tolmie JL.

Eur J Paediatr Neurol. 2010 May;14(3):267-9. doi: 10.1016/j.ejpn.2009.06.007. Epub 2009 Jul 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias